ReviewCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2008
Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory.
Review in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 70 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Glucagon Like Peptide-1 on No-reflow in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Open the trial in the graphChinese People's Liberation Army General Hospital
Who cites it
70 citing papers in PubMed, 6 syntheses or guidelines pooled it, 206 citations in OpenAlex.
- Pooled it
- Guidelines for experimental models of myocardial ischemia and infarction.American journal of physiology. Heart and circulatory physiology · 2018Guideline
- Pooled it
- Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.The Cochrane database of systematic reviews · 2015Pooled it
- Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials.Clinical cardiology · 2013Pooled it
- Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon.BMC cardiovascular disorders · 2013Pooled it
- A randomized controlled clinical trial of prolonged balloon inflation during stent deployment strategy in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a pilot study.BMC cardiovascular disorders · 2022Trial
- In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study.Arquivos brasileiros de cardiologia · 2016Trial
- The value of plasma D-dimer level on admission in predicting no-reflow after primary percutaneous coronary intervention and long-term prognosis in patients with acute ST segment elevation myocardial infarction.Journal of thrombosis and thrombolysis · 2014Trial
- Association between local interleukin-6 levels and slow flow/microvascular dysfunction.Journal of thrombosis and thrombolysis · 2014Trial
- Admission Serum Total Brain-Derived Neurotrophic Factor and Angiographic No-Reflow in Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.Medicina (Kaunas, Lithuania) · 2026Observational
- Red blood cell distribution width/albumin ratio (RAR): A novel predictor of retinal vein occlusion in the Turkish population (STROBE).Medicine · 2026Article
- Stress hyperglycemia ratio and albumin predict in-hospital outcomes in patients with acute myocardial infarction: a cohort study.Scientific reports · 2025Observational
- Association and Prognostic Implications of "No-Reflow Phenomenon" and Hypercoagulability in Patients With ST-Segment Elevation Myocardial Infarction.JACC. Asia · 2025Article
- Novel insights into no-reflow post-PCI: The predictive value of coronary sinus hemodynamics.Global cardiology science & practice · 2025Article
- Breaking the Barrier: Unraveling the No-Reflow Phenomenon in Cardiovascular Medicine.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Review
- Relationship between serum albumin level and hospitalization duration following percutaneous coronary intervention for acute coronary syndrome.Scientific reports · 2024Article
- Prognostic value of fibrinogen-to-albumin ratio combined with coronary calcification score in patients with suspected coronary artery disease.BMC cardiovascular disorders · 2023Article
- Dynamic Behavior of Polymer Microbubbles During Long Ultrasound Tone-Burst Excitation and Its Application for Sonoreperfusion Therapy.Ultrasound in medicine & biology · 2023Article
- Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary no-reflow occurs commonly during acute percutaneous coronary intervention, particularly in patients with acute myocardial infarction and those with degenerated vein grafts. It is associated with a guarded prognosis, and thus needs to be recognized and treated promptly. The pathophysiology originates during the ischemic phase and is characterized by localized and diffuse capillary swelling and arteriolar endothelial dysfunction. In addition, leukocytes become activated and are attracted to the lumen of the capillaries, exhibit diapedesis and may contribute to cellular and intracellular edema and clogging of vessels. At the moment of perfusion, the sudden rush of leukocytes and distal atheroemboli further contributes to impaired tissue perfusion. Shortening the door-to-balloon time, use of glycoprotein IIb/IIIa platelet receptor inhibitors and distal protection devices are predicted to limit the development of no-reflow during percutaneous interventions. Distal intracoronary injection of verapamil, nicardipine, adenosine, and nitroprusside may improve coronary flow in the majority of patients. Hemodynamic support of the patient may be needed in some cases until coronary flow improves.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.